echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > EBV-specific T-cell immunotherapy ATA188 treats multiple sclerosis: positive results were achieved in all dose groups.

    EBV-specific T-cell immunotherapy ATA188 treats multiple sclerosis: positive results were achieved in all dose groups.

    • Last Update: 2020-09-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Multiple sclerosis (MS) is a demyelinating neuropathy in which the insulation (i.e. myelin) on the surface of nerve cells in the patient's brain or spinal cord is damaged and the signal transductive of the nervous system is impaired, leading to a range of possible symptoms that affect the patient's activity, mind, and even mental state.
    positive progress in the treatment of multiple sclerosis (MS) with at Atara, a biopharmaceutical company.
    ATA188 is an allogeneic EBV-specific T-cell immunotherapy.
    latest data show that ATA188 has good tolerance in all four dosage groups, improving persistent disease at any point in time, and increasing numbers of patients exhibit continuous disability improvement (SDI) as doses increase.
    the Ia Multi-Center Open Labeling Study for MS Patients aims to determine the safety, toerability and potential efficacy of ATA188.
    patients were treated with four dose increments (5 x 106, 1 x 107, 2 x 107 and 4 x 107 cells), with 6 patients in the queue 1-3 and 7 patients in the queue 4.
    patients in the queue 1-4 showed SDI at six months and continued to improve for 12 months.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.